Literature DB >> 14645572

Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.

Gregory A Prince1, James J Mond, David D Porter, Kevin C Yim, Steve J Lan, Dennis M Klinman.   

Abstract

CpG oligodeoxynucleotides (ODN) were identified that stimulated immunoglobulin production and cell proliferation in cotton rat cells in vitro. Three of these ODN were used as a mucosal adjuvant in the noses of cotton rats immunized via this route with respiratory syncytial virus fusion (F) protein. The CpG ODN markedly increased the cotton rat humoral neutralizing-antibody response to respiratory syncytial virus. Such immunized animals had a marked reduction in the production of infectious virus after a live-virus challenge. Animals immunized with the combination of F protein and CpG developed enhanced pulmonary pathology consisting of alveolitis and interstitial pneumonitis after a live-virus challenge. Similar enhanced disease has been seen in cotton rats and children immunized with formalin-inactivated respiratory syncytial virus.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14645572      PMCID： PMC296064          DOI： 10.1128/jvi.77.24.13156-13160.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  28 in total

1.  CpG motifs as immune adjuvants.

Authors:  D M Klinman; K M Barnhart; J Conover
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

2.  Respiratory syncytial virus vaccine development.

Authors:  J E Crowe
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

Review 3.  The potential of CpG oligodeoxynucleotides as mucosal adjuvants.

Authors:  M J McCluskie; R D Weeratna; P J Payette; H L Davis
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

4.  The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation.

Authors:  A J McCarthy; H M Kingman; C Kelly; G S Taylor; E O Caul; D Grier; J Moppett; A B Foot; J M Cornish; A Oakhill; C G Steward; D H Pamphilon; D I Marks
Journal:  Bone Marrow Transplant       Date:  1999-12       Impact factor: 5.483

5.  Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.

Authors:  W S Gallichan; R N Woolstencroft; T Guarasci; M J McCluskie; H L Davis; K L Rosenthal
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

6.  Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.

Authors:  G A Prince; C Capiau; M Deschamps; L Fabry; N Garçon; D Gheysen; J P Prieels; G Thiry; O Van Opstal; D D Porter
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).

Authors:  G E Hancock; K M Heers; J D Smith; C A Scheuer; A R Ibraghimov; K S Pryharski
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

Review 8.  Immune-mediated disease pathogenesis in respiratory syncytial virus infection.

Authors:  B S Graham; T R Johnson; R S Peebles
Journal:  Immunopharmacology       Date:  2000-07-25

Review 9.  Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden.

Authors:  L L Han; J P Alexander; L J Anderson
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

Review 10.  Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

Authors:  M Pizza; M M Giuliani; M R Fontana; E Monaci; G Douce; G Dougan; K H Mills; R Rappuoli; G Del Giudice
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641
View more
  21 in total

1.  Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus).

Authors:  Jessica L Grieves; Zhiwei Yin; Russell K Durbin; Joan E Durbin
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

2.  The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Yu-Jin Jung; Subbiah Jeeva; Young-Man Kwon; Baik Lin Seong; Sang Moo Kang
Journal:  Antiviral Res       Date:  2019-05-28       Impact factor: 5.970

Review 3.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

4.  CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.

Authors:  Lei Zhang; Hongyong Li; Yan Hai; Wei Yin; Wenjian Li; Boyang Zheng; Xiaomin Du; Na Li; Zhengzheng Zhang; Yuqing Deng; Ruihong Zeng; Lin Wei
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

5.  RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.

Authors:  Na Li; Ling Zhang; Boyang Zheng; Wenjian Li; Jianxun Liu; Huixian Zhang; Ruihong Zeng
Journal:  Hum Vaccin Immunother       Date:  2019-04-29       Impact factor: 3.452

6.  The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.

Authors:  Kevin C Yim; Clifford J Carroll; Ana Tuyama; Natalia Cheshenko; Maria Josefina Carlucci; David D Porter; Gregory A Prince; Betsy C Herold
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

8.  Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes.

Authors:  Shiou-Chih Hsu; Chih-Peng Chang; Chao-Yuan Tsai; Shih-Hung Hsieh; Betty A Wu-Hsieh; Yu-Shu Lo; Jinn-Moon Yang
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

9.  Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.

Authors:  Youri Lee; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Soojin Park; Young-Man Kwon; Sang Moo Kang
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

10.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Authors:  Teresa R Johnson; Srinivas Rao; Robert A Seder; Man Chen; Barney S Graham
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.